153 related articles for article (PubMed ID: 22616681)
1. The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens.
Haeseker M; Stolk L; Nieman F; Hoebe C; Neef C; Bruggeman C; Verbon A
Br J Clin Pharmacol; 2013 Jan; 75(1):180-5. PubMed ID: 22616681
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg.
Szałek E; Tomczak H; Kamińska A; Grabowski T; Smuszkiewicz P; Matysiak K; Wolc A; Kaczmarek Z; Grześkowiak E
Adv Med Sci; 2012; 57(2):217-23. PubMed ID: 22968336
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH; Firsov AA
Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.
Gai XY; Bo SN; Shen N; Zhou QT; Yin AY; Lu W
Chin Med J (Engl); 2019 Mar; 132(6):638-646. PubMed ID: 30855292
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries.
Varela JE; Cohn SM; Brown M; Ward CG; Namias N; Spalding PB
J Antimicrob Chemother; 2000 Mar; 45(3):337-42. PubMed ID: 10702553
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.
Saengsuwan P; Jaruratanasirikul S; Jullangkoon M; Aeinlang N
J Med Assoc Thai; 2010 Jul; 93(7):784-8. PubMed ID: 20649056
[TBL] [Abstract][Full Text] [Related]
8. Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans.
Szałek E; Połom W; Karbownik A; Grabowski T; Konkołowicz A; Wolc A; Matuszewski M; Krajka K; Grześkowiak E
Pharmacol Rep; 2012; 64(3):673-9. PubMed ID: 22814020
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Scaglione F; Mouton JW; Mattina R; Fraschini F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
[TBL] [Abstract][Full Text] [Related]
10. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
[TBL] [Abstract][Full Text] [Related]
11. Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility.
Gieling EM; Wallenburg E; Frenzel T; de Lange DW; Schouten JA; Ten Oever J; Kolwijck E; Burger DM; Pickkers P; Ter Heine R; Brüggemann RJM
Clin Pharmacol Ther; 2020 Oct; 108(4):770-774. PubMed ID: 32298468
[TBL] [Abstract][Full Text] [Related]
12. Defining optimal dosing of ciprofloxacin in patients with septic shock.
Roberts JA; Alobaid AS; Wallis SC; Perner A; Lipman J; Sjövall F
J Antimicrob Chemother; 2019 Jun; 74(6):1662-1669. PubMed ID: 30809648
[TBL] [Abstract][Full Text] [Related]
13. Is the standard dose of amoxicillin-clavulanic acid sufficient?
Haeseker M; Havenith T; Stolk L; Neef C; Bruggeman C; Verbon A
BMC Pharmacol Toxicol; 2014 Jul; 15():38. PubMed ID: 25047044
[TBL] [Abstract][Full Text] [Related]
14. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.
Zelenitsky S; Ariano R; Harding G; Forrest A
Antimicrob Agents Chemother; 2005 Oct; 49(10):4009-14. PubMed ID: 16189073
[TBL] [Abstract][Full Text] [Related]
15. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
Firsov AA; Vostrov SN; Shevchenko AA; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
[TBL] [Abstract][Full Text] [Related]
16. Ciprofloxacin pharmacokinetics in burn patients.
Garrelts JC; Jost G; Kowalsky SF; Krol GJ; Lettieri JT
Antimicrob Agents Chemother; 1996 May; 40(5):1153-6. PubMed ID: 8723457
[TBL] [Abstract][Full Text] [Related]
17. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.
Bowker KE; Wootton M; Rogers CA; Lewis R; Holt HA; MacGowan AP
J Antimicrob Chemother; 1999 Nov; 44(5):661-7. PubMed ID: 10552983
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Lister PD; Sanders CC
Antimicrob Agents Chemother; 1999 May; 43(5):1118-23. PubMed ID: 10223923
[TBL] [Abstract][Full Text] [Related]
19. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
Firsov AA; Zinner SH; Lubenko IYu ; Vostrov SN
Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
